Cerus (CERS) Phase 3 Clinical Trial of INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients Met its Primary Efficacy Endpoint

Visit StreetInsider.com at http://www.streetinsider.com/Trading+Halts/Cerus+%28CERS%29+Phase+3+Clinical+Trial+of+INTERCEPT+Blood+System+for+Red+Blood+Cells+in+Cardiovascular+Surgery+Patients+Met+its+Primary+Efficacy+Endpoint/22948465.html for the full story.

Leave a Reply

Your email address will not be published. Required fields are marked *